ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

NCT06345157 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

379

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: Ofatumumab

Sponsor

Novartis Pharmaceuticals